EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma

Shwan Abdullah Hamad, Zhila Salam Othman, Shilan Hiwa Hama Salih, Trefa Mohammed Abdullah

RSC Pharmaceutics · 2026 · 3 (3) · 799-808

DOI: 10.1039/d5pm00261c ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Shwan Abdullah Hamad und 3 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Levodopa (LD) remains the most effective therapy for Parkinson’s disease, but its short plasma half-life requires frequent dosing and causes fluctuating drug levels and motor complications. Controlled delivery systems may help stabilise LD release.

Zitieren

APA

Hamad, S. A., Othman, Z. S., Salih, S. H. H., & Abdullah, T. M. (2026). Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma. RSC Pharmaceutics, 3(3), 799-808. https://doi.org/10.1039/d5pm00261c

Vancouver

Hamad SA, Othman ZS, Salih SHH, Abdullah TM. Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma. RSC Pharmaceutics. 2026;3(3):799-808. doi:10.1039/d5pm00261c

BibTeX
@article{Hamad2026,
  author = {Hamad, Shwan Abdullah and Othman, Zhila Salam and Salih, Shilan Hiwa Hama and Abdullah, Trefa Mohammed},
  title = {Kinetic modelling and in vitro release mechanism of levodopa from sporopollenin-based microcapsules in human blood plasma},
  journal = {RSC Pharmaceutics},
  year = {2026},
  volume = {3},
  number = {3},
  pages = {799--808},
  doi = {10.1039/d5pm00261c}
}
Kostenlos starten →